A Relative Bioavailability Food Effect Study of LY03005
Status:
Completed
Trial end date:
2019-02-16
Target enrollment:
Participant gender:
Summary
The objective if this study is to assess the relative bio-availability of single oral doses
of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions
in a 2-period, crossover trial.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Treatments:
Desvenlafaxine Succinate Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Serotonin and Noradrenaline Reuptake Inhibitors